Clinical Trial Detail

NCT ID NCT04023526
Title A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

acute myeloid leukemia

Therapies

ARGX-110 + Azacitidine

Age Groups: adult senior

No variant requirements are available.